Table 5:
Risk factors for episodes of UTI and urosepsis during the entire observation period in ADPKD patients.
| Univariable | Multivariable b | |||||
|---|---|---|---|---|---|---|
| UTI and/or urosepsis during the entire observation period | RR a | 95%CI | P value | RR a | 95%CI | P value |
| Recipient age at Tx (per 5 years) | 1.06 | 1.03; 1.10 | .001 | 1.05 | 1.02; 1.08 | .003 |
| Waiting time (per 12 months) | 1.00 | 0.99; 1.01 | .396 | |||
| Female recipient (yes vs no) | 1.42 | 0.68; 2.97 | .356 | |||
| Recipient diabetes mellitus (yes vs no) | 0.58 | 0.20; 1.70 | .322 | |||
| Recipient BMI (per 1 kg/m2) | 1.00 | 0.91; 1.10 | .923 | |||
| Recipient CCI score (per 1 point) | 1.52 | 1.15; 2.02 | .003 | |||
| Unilateral nephrectomy before Tx (yes vs no) | 0.57 | 0.26; 1.24 | .157 | 0.64 | 0.32; 1.29 | .209 |
| Donor age (per 5 years) | 1.03 | 1.01; 1.06 | .011 | |||
| Donor eGFRcr (per 5 ml/min/1.73 m2) | 0.98 | 0.97; 1.00 | .040 | |||
| Living donor (yes vs no) | 0.48 | 0.22; 1.06 | .071 | |||
| Preemptive Tx (yes vs no) | 0.80 | 0.26; 2.45 | .703 | |||
| AB0compatible Tx (yes vs no) | 1.47 | 0.34; 6.41 | .605 | |||
| Steroids (yes vs no) | 3.06 | 2.12; 4.43 | <.001 | 3.04 | 2.11; 4.38 | <.001 |
| Cyclosporine A (yes vs no) | 1.87 | 0.70; 4.94 | .221 | |||
| Tacrolimus (yes vs no) | 0.57 | 0.32; 0.98 | .039 | |||
| Everolimus (yes vs no) | 0.79 | 0.39; 1.60 | .513 | |||
| Belatacept (yes vs no) | 0.47 | 0.17; 1.27 | .135 | 0.61 | 0.24; 1.56 | .306 |
| Mycophenolate (yes vs no) | 1.67 | 0.76; 3.67 | .204 | |||
| Rejection episode (yes vs no) | 2.58 | 1.11; 5.95 | .027 | 2.01 | 0.98; 4.12 | .056 |
Patients were censored from the time at which both native kidneys had been removed. In 22 patients both native kidneys had been removed before Tx. In 15 patients the second kidney was removed after Tx. Maintenance immunosuppression changed during the observation period. Immunosuppression at diagnosis is shown. Immunosuppression with <10 years of total exposure time (entire observation period of all patients) was excluded to assure reliable estimates: basiliximab, fingolimod, sotrastaurin.
Relative risk estimated by a multilevel mixed-effects Poisson regression model.
Multivariable model was identified by LASSO regression.
Abbreviations: ADPKD, polycystic kidney disease; BMI, body mass index; CCI, Charlson Comorbidity Index; CI, confidence interval; eGFRcr, creatinine-based estimated glomerular filtration rate; Tx, transplantation.